The DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Open accessAbstract
Metastatic prostate cancer is treated with drugs that antagonize androgen action, but most patients progress to a more aggressive form of the disease called castration-resistant prostate cancer, driven by elevated expression of the androgen receptor. Here we characterize the diarylthiohydantoins RD162 and MDV3100, two compounds optimized from a screen for nonsteroidal antiandrogens that retain activity in the setting of increased androgen receptor expression. Both compounds bind to the androgen receptor with greater relative affinity than the clinically used antiandrogen bicalutamide, reduce the efficiency of its nuclear translocation, and impair both DNA binding to androgen response elements and recruitment of coactivators. RD162 and MDV3100 are orally available and induce tumor regression in mouse models of castration-resistant human prostate cancer. Of the first 30 patients treated with MDV3100 in a Phase I/II clinical trial, 13 of 30 (43%) showed sustained declines (by >50%) in serum concentrations of prostate-specific antigen, a biomarker of prostate cancer. These compounds thus appear to be promising candidates for treatment of advanced prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The ability of these molecules to inhibit AR transcriptional activity and demonstrate clinical efficacy in a phase I/II trial of patients with CR tumors, in the case of MDV 3100, suggests that ligand-directed therapeutics might still have a place in future treatment regimes.”
From Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer (2011) · cites this paper as [81]
In the citing paper
“The ability of these molecules to inhibit AR transcriptional activity and demonstrate clinical efficacy in a phase I/II trial of patients with CR tumors, in the case of MDV 3100, suggests that ligand-directed therapeutics might still have a place in future treatment regimes.”
From Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer (2011) · cites this paper as [81]
In the citing paper
“EPI-001 targets the NTD of the AR (80), whereas MDV 3100 binds to the LBD (81), similarly to bicalutamide.”
From Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer (2011) · cites this paper as [81]
In the citing paper
“The ARE repeat reporter (4X-ARE, firefly luciferase) has been previously described (Tran et al., 2009).”
From Allosteric interactions prime androgen receptor dimerization and activation (2022) · cites this paper as Tran et al., 2009
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,759
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Self-citationScher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
Self-citationStructural basis for antagonism and resistance of bicalutamide in prostate cancer
Bohl, C. E., Gao, W., Miller, D. D., Bell, C. E., & Dalton, J. T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500381102 · Cited by 426
Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence
Taplin, M., & Balk, S. P. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10653 · Cited by 392
Larson, S. M., Morris, M. J., Guenther, I., Beattie, B., Humm, J. L., Akhurst, T., Finn, R. D., Erdi, Y. E., Pentlow, K. S., Dyke, J., et al. (2004) · PubMed · Cited by 298
Self-citationMasiello, D., Cheng, S., Bubley, G. J., Lu, M. L., & Balk, S. P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203310200 · Cited by 240
Yoshida, T., Kinoshita, H., Segawa, T., Nakamura, E., Inoue, T., Shimizu, Y., Kamoto, T., & Ogawa, O. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0817 · Cited by 178
Hodgson, M. C., Astapova, I. I., Cheng, S., Lee, L. J., Verhoeven, M. C., Choi, E., Balk, S. P., & Hollenberg, A. N. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408972200 · Cited by 143
Homozygous Deletions and Recurrent Amplifications Implicate New Genes Involved in Prostate Cancer
Liu, W., Xie, C., Zhu, Y., Li, T., Sun, J., Cheng, Y., Ewing, C. M., Dalrymple, S. L., Turner, A. R., Sun, J., et al. (2008) · Neoplasia · doi:10.1593/neo.08428 · Cited by 128
Research works printed but not linked: 1
- Larson S. M., et al.., J. Nucl. Med. 45, 366 (2004).15001675
Cited by
Sorted by citations
Items 601–700 of 1,000
Identification of a Clinically Relevant Androgen-Dependent Gene Signature in Prostate Cancer
Heemers, H. V., Schmidt, L. J., Sun, Z., Regan, K. M., Anderson, S. K., Duncan, K., Wang, D., Liu, S., Ballman, K. V., & Tindall, D. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2512 · Cited by 43
Targeting the Androgen Receptor with Steroid Conjugates
Levine, P. M., Garabedian, M. J., & Kirshenbaum, K. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500101h · Cited by 43
Androgen Action During Prostate Carcinogenesis
Wang, D., & Tindall, D. J. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-243-4_2 · Cited by 43
Lebbe, M., TAYLOR, A. E. R., Visser, J. A., Kirkman‐Brown, J., Woodruff, T. K., & Arlt, W. (2017) · Endocrinology · doi:10.1210/en.2016-1851 · Cited by 43
Chong, J. T., Oh, W. K., & Liaw, B. C.-H. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s147168 · Cited by 43
Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer
Wang, K., Ruan, H., Xu, T., Liu, L., Liu, D., Yang, H., Zhang, X., & Chen, K. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s159777 · Cited by 43
Redefining hormone resistance in prostate cancer
Hoimes, C. J., & Kelly, W. K. (2009) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009356433 · Cited by 43
Smith, M. R., Fred Saad, C., Rathkopf, D. E., Mulders, P., Bono, J. S. D., Small, E. J., Shore, N. D., Fizazi, K. S., Kheoh, T. S., Li, J., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.03.007 · Cited by 43
Tang, S., Sethunath, V., Metaferia, N. Y., Nogueira, M. F., Gallant, D. S., Garner, E. R., Lairson, L. A., Penney, C. M., Li, J., Gelbard, M. K., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110417 · Cited by 42
Conformational dynamics of androgen receptors bound to agonists and antagonists
Gim, H. J., Park, J., Jung, M. E., & Houk, K. N. (2021) · Scientific Reports · doi:10.1038/s41598-021-94707-2 · Cited by 42
Self-citationCharacterization of Niphatenones that Inhibit Androgen Receptor N-Terminal Domain
Banuelos, C. A., Lal, A., Tien, A. H., Shah, N., Yang, Y. C., Mawji, N. R., Meimetis, L. G., Park, J., Jian, K., Andersen, R. J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107991 · Cited by 43
Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists
Joseph, J. D., Wittmann, B. M., Dwyer, M. A., Cui, H. N., Dye, D. A., McDonnell, D. P., & Norris, J. D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900185106 · Cited by 42
GnRH agonists and the rapidly increasing use of combined androgen blockade in prostate cancer
Labrie, F. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0165 · Cited by 42
Wen, S., Niu, Y., Lee, S. O., Yeh, S., Shang, Z., Gao, H., Li, Y., Chou, F.-J., & Chang, C. (2016) · Molecular Carcinogenesis · doi:10.1002/mc.22468 · Cited by 42
Non-canonical AR activity facilitates endocrine resistance in breast cancer
Chia, K., Milioli, H. H., Portman, N., Laven‐Law, G., Coulson, R. S., Yong, A., Segara, D., Parker, A., Caldon, C. E., Deng, N., et al. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0333 · Cited by 42
Zhang, Y., Wu, X., Xue, X., Li, C., Wang, J., Wang, R., Zhang, C., Wang, C., Shi, Y., Zou, L., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00327 · Cited by 43
Androgen receptor modulators: a review of recent patents and reports (2012-2018)
Fujii, S., & Kagechika, H. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1618831 · Cited by 43
Androgen receptor co-regulation in prostate cancer
Senapati, D., Kumari, S., & Heemers, H. V. (2019) · Asian journal of urology · doi:10.1016/j.ajur.2019.09.005 · Cited by 45
Michmerhuizen, A. R., Chandler, B. C., Olsen, E. C., Wilder-Romans, K., Moubadder, L., Liu, M., Pesch, A. M., Zhang, A., Ritter, C. L., Ward, S., et al. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00035 · Cited by 42
Kim, T. J., Lee, Y. H., & Koo, K. C. (2021) · Biomolecules · doi:10.3390/biom11040492 · Cited by 43
Lai, L. Y., Oerline, M., Caram, M. E. V., Tsao, P. A., Kaufman, S. R., Hollenbeck, B. K., & Shahinian, V. B. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac081 · Cited by 44
YAP antagonizes TEAD‐mediated AR signaling and prostate cancer growth
Zhuo, S., Li, X., Cho, Y. S., Liu, Y., Yang, Y., Zhu, J., & Jiang, J. (2023) · The EMBO Journal · doi:10.15252/embj.2022112184 · Cited by 44
Androgen Physiology: Receptor and Metabolic Disorders
McEwan, I. J., & Brinkmann, A. O. (2016) · Cited by 42
Nelius, T., Rinard, K., & Filleur, S. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.12.006 · Cited by 41
Androgen Receptor Gene Rearrangements: New Perspectives on Prostate Cancer Progression
Brand, L. J., & Dehm, S. M. (2013) · Current Drug Targets · doi:10.2174/1389450111314040005 · Cited by 42
SULT2B1b Sulfotransferase: Induction by Vitamin D Receptor and Reduced Expression in Prostate Cancer
Seo, Y., Mirkheshti, N., Song, C. S., Kim, S., Dodds, S. G., Ahn, S., Christy, B. A., Mendez-Meza, R., Ittmann, M., Abboud‐Werner, S. L., et al. (2013) · Molecular Endocrinology · doi:10.1210/me.2012-1369 · Cited by 41
Nucleic acid-based tissue biomarkers of urologic malignancies
Dietrich, D., Meller, S., Uhl, B., Ralla, B., Stephan, C., Jung, K., Ellinger, J., & Kristiansen, G. (2014) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2014.906130 · Cited by 41
Ubiquitylation of nuclear receptors: new linkages and therapeutic implications
Helzer, K. T., Hooper, C., Miyamoto, S., & Alarid, E. T. (2015) · Journal of Molecular Endocrinology · doi:10.1530/jme-14-0308 · Cited by 43
Targeting Pioneering Factor and Hormone Receptor Cooperative Pathways to Suppress Tumor Progression
Shah, S., Prasad, S., & Knudsen, K. E. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-0943 · Cited by 41
Liu, H., Wang, L., Tian, J., Li, J., & Liu, H. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25928 · Cited by 41
Guo, C., Yeh, S., Niu, Y., Li, G., Zheng, J., Li, L., & Chang, C. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.022 · Cited by 42
Yadav, S. S., Li, J., Stockert, J. A., Herzog, B. J., O'Connor, J., Garzon-Manco, L., Parsons, R. E., Tewari, A. K., & Yadav, K. K. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.01.011 · Cited by 41
Sharma, N. V., Pellegrini, K. L., Ouellet, V., Giuste, F., Ramalingam, S. S., Watanabe, K. A., Adam-Granger, É., Fossouo, L., You, S., Freeman, M. R., et al. (2018) · Cancers · doi:10.3390/cancers10100379 · Cited by 41
Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer
Narayanan, R. (2020) · Asian journal of urology · doi:10.1016/j.ajur.2020.03.002 · Cited by 41
Hara, T., Ushio, K., Nishiwaki, M., Kouno, J., Araki, H., Hikichi, Y., Hattori, M., Imai, Y., & Yamaoka, M. (2009) · Cell Biology International · doi:10.1042/cbi20090030 · Cited by 41
Histone H2A Lys130 acetylation epigenetically regulates androgen production in prostate cancer
Nguyen, T., Sridaran, D., Chouhan, S., Weimholt, C., Wilson, A., Luo, J. R., Li, T., Koomen, J. M., Fang, B., Putluri, N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38887-7 · Cited by 40
Leibowitz‐Amit, R., & Joshua, A. M. (2012) · Current Oncology · doi:10.3747/co.19.1281 · Cited by 40
Bone-targeting agents in prostate cancer
Suzman, D. L., Boikos, S. A., & Carducci, M. A. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9480-2 · Cited by 40
Update on options for treatment of metastatic castration-resistant prostate cancer
Tan, X. (2010) · OncoTargets and Therapy · doi:10.2147/ott.s5818 · Cited by 40
Chen, J., Li, L., Yang, Z., Luo, J., Yeh, S., & Chang, C. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.08.014 · Cited by 40
Olson, P. D., McLellan, L. K., Hreha, T. N., Liu, A., Briden, K. E., Hruska, K. A., & Hunstad, D. A. (2018) · Kidney International · doi:10.1016/j.kint.2018.04.023 · Cited by 40
The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer
El-Amm, J., & Aragon‐Ching, J. B. (2019) · Clinical Medicine Insights Oncology · doi:10.1177/1179554919833927 · Cited by 40
Terada, N., Shimizu, Y., Yoshida, T., Maeno, A., Kamba, T., Inoue, T., Nakamura, E., Kamoto, T., & Ogawa, O. (2009) · The Prostate · doi:10.1002/pros.21058 · Cited by 40
Nadal, R., Zhang, Z., Rahman, H., Schweizer, M. T., Denmeade, S. R., Paller, C. J., Carducci, M. A., Eisenberger, M. A., & Antonarakis, E. S. (2014) · The Prostate · doi:10.1002/pros.22874 · Cited by 39
Progression in immunotherapy for advanced prostate cancer
Liang, H., Liu, Y., Guo, J., Dou, M., Zhang, X., Hu, L., & Chen, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1126752 · Cited by 40
An expanded metabolic pathway for androgen production by commensal bacteria
Wang, T., Ahmad, S., Cruz-Lebrón, A., Ernst, S. E., Caicedo, K. Y. O., Jeong, Y., Binion, B., Mbuvi, P., Dutta, D., Fernández-Materán, F. V., et al. (2025) · Nature Microbiology · doi:10.1038/s41564-025-01979-9 · Cited by 42
Enzalutamide: Development from bench to bedside
Bambury, R. M., & Scher, H. I. (2015) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2014.12.017 · Cited by 39
Self-citationNovel, Potent Anti-Androgens of Therapeutic Potential: Recent Advances and Promising Developments
Vasaitis, T. S., & Njar, V. C. O. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.14 · Cited by 39
Luo, J. (2016) · Asian Journal of Andrology · doi:10.4103/1008-682x.178490 · Cited by 41
Pushing estrogen receptor around in breast cancer
Lim, E., Tarulli, G. A., Portman, N., Hickey, T. E., Tilley, W. D., & Palmieri, C. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0427 · Cited by 40
Moretti, C., Guccione, L., Giacinto, P. D., Simonelli, I., Exacoustós, C., Toscano, V., Motta, C., Leo, V. D., Petraglia, F., & Lenzi, A. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01186 · Cited by 39
Kokal, M., Mirzakhani, K., Pungsrinont, T., & Baniahmad, A. (2020) · Cancers · doi:10.3390/cancers12071833 · Cited by 39
Zhang, Y., Kim, K., Zhang, W., Guo, Y., Kim, S., & Lü, J. (2011) · International Journal of Cancer · doi:10.1002/ijc.25993 · Cited by 39
Merseburger, A. S., Hammerer, P., Rozet, F., Roumeguère, T., Caffo, O., da Silva, F. C., & Alcaraz, A. (2014) · World Journal of Urology · doi:10.1007/s00345-014-1406-2 · Cited by 39
The RB tumor suppressor: a gatekeeper to hormone independence in prostate cancer?
Macleod, K. F. (2010) · Journal of Clinical Investigation · doi:10.1172/jci45406 · Cited by 39
Donato, M. D., Giovannelli, P., Migliaccio, A., & Castoria, G. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01008-4 · Cited by 38
Li, Y., Zhu, S., Chen, Y., Ma, Q., Kan, D., Yu, W., Zhang, B., Chen, X., Wei, W., Shao, Y., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05773-5 · Cited by 38
Self-citationKim, W. K., Buckley, A. J., Lee, D., Hiroto, A., Nenninger, C. H., Olson, A. W., Wang, J., Li, Z., Vikram, R., Adzavon, Y. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45489-4 · Cited by 39
Is there an antiandrogen withdrawal syndrome with enzalutamide?
Rodríguez‐Vida, A., Bianchini, D., Hemelrijck, M. V., Hughes, S. R., Malik, Z., Powles, T. B., Bahl, A. K., Rudman, S. M., Payne, H. A., Bono, J. S. D., et al. (2014) · British Journal of Urology · doi:10.1111/bju.12826 · Cited by 38
Bennett, D., Gibbons, J. A., Mol, R., Ohtsu, Y., & Williard, C. V. (2013) · Bioanalysis · doi:10.4155/bio.13.325 · Cited by 38
Cui, Y., Nadiminty, N., Liu, C., Lou, W., Schwartz, C. T., & Gao, A. C. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0107 · Cited by 38
Significance of microRNAs in Androgen Signaling and Prostate Cancer Progression
Takayama, K., Misawa, A., & Inoue, S. (2017) · Cancers · doi:10.3390/cancers9080102 · Cited by 38
Hughes, D. L. (2020) · Organic Process Research & Development · doi:10.1021/acs.oprd.0c00005 · Cited by 38
OncoLoop: A Network-Based Precision Cancer Medicine Framework
Vasciaveo, A., Arriaga, J. M., de Almeida, F. N., Zou, M., Douglass, E. F., Picech, F., Shibata, M., Rodríguez-Calero, A., de Brot, S., Mitrofanova, A., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0342 · Cited by 38
Molecular pathology and prostate cancer therapeutics: from biology to bedside
Rodrigues, D. N., Butler, L. M., Estelles, D. L., & Bono, J. S. D. (2013) · The Journal of Pathology · doi:10.1002/path.4272 · Cited by 38
1,2,4-Oxadiazoles: A new class of anti-prostate cancer agents
Khatik, G. L., Kaur, J., Kumar, V., Tikoo, K., & Nair, V. A. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.01.059 · Cited by 38
20(S)-Protopanaxadiol Inhibition of Progression and Growth of Castration-Resistant Prostate Cancer
Cao, B., Qi, Y., Yang, Y., Liu, X., Xu, D., Guo, W., Zhan, Y., Xiong, Z., Zhang, A., Wang, A. R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111201 · Cited by 38
Ferretti, S., Mercinelli, C., Marandino, L., Litterio, G., Marchioni, M., & Schips, L. (2023) · Research and Reports in Urology · doi:10.2147/rru.s385257 · Cited by 38
Pharmacology and Clinical Use of Sex Steroid Hormone Receptor Modulators
Cleve, A., Fritzemeier, K., Haendler, B., Heinrich, N., Möller, C., Schwede, W., & Wintermantel, T. M. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-30726-3_24 · Cited by 40
Crafting precise multivalent architectures
Levine, P. M., Carberry, T. P., Holub, J. M., & Kirshenbaum, K. (2013) · MedChemComm · doi:10.1039/c2md20338c · Cited by 40
Effect of N-methyl deuteration on metabolism and pharmacokinetics of enzalutamide
Jiang, J., Pang, X., Dai, X., Diao, X., Chen, X., Zhong, D., Chen, Y., Li, L., & Wang, Y. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s111352 · Cited by 37
Self-citationLu, H., Wang, T., Li, J., Fedele, C., Liu, Q., Zhang, J., Jiang, Z., Jain, D., Iozzo, R. V., Violette, S. M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0543 · Cited by 37
Armstrong, A. J., Fred Saad, C., Phung, D., Dmuchowski, C., Shore, N. D., Fizazi, K. S., Hirmand, M., Forer, D., Scher, H. I., & Bono, J. S. D. (2017) · Cancer · doi:10.1002/cncr.30587 · Cited by 37
Self-citationKita, Y., Goto, T., Akamatsu, S., Yamasaki, T., Inoue, T., Ogawa, O., & Kobayashi, T. (2018) · Cancers · doi:10.3390/cancers10100345 · Cited by 40
Sekhar, K. R., Wang, J., Freeman, M. L., & Kirschner, A. N. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214670 · Cited by 37
Verma, S., Shankar, E., Chan, E. R., & Gupta, S. (2020) · Cells · doi:10.3390/cells9122535 · Cited by 38
Mitsiades, N., & Kaochar, S. (2021) · Endocrine Related Cancer · doi:10.1530/erc-21-0098 · Cited by 39
Identification of Novel Androgen Receptor Antagonists Using Structure- and Ligand-Based Methods
Li, H., Ren, X., Leblanc, E., Frewin, K., Rennie, P. S., & Cherkasov, A. R. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci300514v · Cited by 37
Cell mates: paracrine and stromal targets for prostate cancer therapy
Sluka, P., & Davis, I. D. (2013) · Nature Reviews Urology · doi:10.1038/nrurol.2013.146 · Cited by 36
Kohli, M., Wang, L., Xie, F., Sicotte, H., Yin, P., Dehm, S. M., Hart, S. N., Vedell, P. T., Barman, P., Qin, R., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0145176 · Cited by 36
Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer
Wadosky, K. M., & Koochekpour, S. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.14090 · Cited by 39
Therapeutic Targeting of Sunitinib-Induced AR Phosphorylation in Renal Cell Carcinoma
Adelaiye-Ogala, R. M., Damayanti, N. P., Orillion, A. R., Arisa, S., Chintala, S., Titus, M. A., Kao, C. H., & Пили, Р. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3386 · Cited by 36
Lombard, A. P., Liu, L., Cucchiara, V., Liu, C., Armstrong, C. M., Zhao, R., Yang, J. C., Lou, W., Evans, C. P., & Gao, A. C. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1269 · Cited by 36
Werner, C. K., Nna, U. J., Sun, H., Wilder-Romans, K., Dresser, J., Kothari, A. U., Zhou, W., Yao, Y., Rao, A. U. K., Stallard, S., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0095 · Cited by 36
ACK1–AR and AR–HOXB13 signaling axes: epigenetic regulation of lethal prostate cancers
Kim, E. H., Cao, D., Mahajan, N. P., Andriole, G. L., & Mahajan, K. N. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa018 · Cited by 37
Zhou, J., Wang, Y., Wu, D., Wang, S., Chen, Z., Xiang, S., & Chan, F. L. (2021) · Oncogene · doi:10.1038/s41388-021-01737-1 · Cited by 36
Sharifi, N., McPhaul, M. J., & Auchus, R. J. (2010) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e3181ff6bb8 · Cited by 36
Metastatic Castration-Resistant Prostate Cancer: Time for Innovation
Tucci, M., Scagliotti, G. V., & Vignani, F. (2015) · Future Oncology · doi:10.2217/fon.14.145 · Cited by 36
Raheem, O. A., Kulidjian, A., Wu, C., Jeong, Y. B., Yamaguchi, T., Smith, K. M., Goff, D. J., Leu, H. S., Morris, S., Cacalano, N. A., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-185 · Cited by 36
HLBT-100: a highly potent anti-cancer flavanone from Tillandsia recurvata (L.) L.
Lowe, H. I. C., Toyang, N. J., Watson, C. T., Ayeah, K., & Bryant, J. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0404-z · Cited by 36
MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer
Crowell, P. D., Giafaglione, J. M., Jones, A. E., Nunley, N. M., Hashimoto, T., Delcourt, A. M. L., Petcherski, A., Agrawal, R., Bernard, M. J., Diaz, J. A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113221 · Cited by 35
Androgen receptor is a determinant of melanoma targeted drug resistance
Samarkina, A., Youssef, M. K., Ostano, P., Ghosh, S., Ma, M., Tassone, B., Proust, T., Chiorino, G., Levesque, M. P., Goruppi, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42239-w · Cited by 37
Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer
Madan, R. A., & Gulley, J. L. (2011) · Expert Review of Vaccines · doi:10.1586/erv.10.173 · Cited by 35
Muniyan, S., Chou, Y.-W., Ingersoll, M. A., Devine, A., Morris, M., Odero‐Marah, V., Khan, S. A., Chaney, W. G., Bu, X. R., & Lin, M. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.07.002 · Cited by 35
Zhang, X., Castanotto, D., Nam, S., Horne, D. A., & Stein, C. A. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.017 · Cited by 35
Kumano, Y., Hasegawa, Y., Kawahara, T., Yasui, M., Miyoshi, Y., Matsubara, N., & Uemura, H. (2019) · BioMed Research International · doi:10.1155/2019/9450838 · Cited by 35
Velasco, M. A. D., Kura, Y., Sakai, K., Hatanaka, Y., Davies, B. R., Campbell, H., Klein, S., Kim, Y. S., MacLeod, A. R., Sugimoto, K., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.122688 · Cited by 37
Liu, B., Sun, Y., Tang, M. M., Liang, C., Huang, C., Niu, Y., Wang, Z., & Chang, C. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02932-w · Cited by 36
Targeting Mitochondrial Metabolism in Prostate Cancer with Triterpenoids
Mamouni, K., Kallifatidis, G., & Lokeshwar, B. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052466 · Cited by 37
Functional mapping of androgen receptor enhancer activity
Huang, C.-C. F., Lingadahalli, S., Morova, T., Özturan, D., Hu, E., Yu, I. P. L., Linder, S., Hoogstraat, M., Stelloo, S., Sar, F., et al. (2021) · Genome biology · doi:10.1186/s13059-021-02339-6 · Cited by 36
Metadata
- Authors
- Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., Wasielewska, T., Welsbie, D., Chen, C. D., Higano, C. S., Beer, T. M., Hung, D. T., Scher, H. I., Jung, M. E., & Sawyers, C. L.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- University of California, Los Angeles (US)
- University of Washington (US)
- Oregon Health & Science University (US)
- Medivation, Inc. (United States) (US)
- Corresponding author
- Tran, Chris
- Ouk, Samedy
- Chen, Charlie Degui
- Jung, Michael E.
- Sawyers, Charles L.
- ORCID
- Venue
- Science
- Published
- 2009-05-08
- Volume
- 324
- Issue
- 5928
- Pages
- 787-790
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC2981508
- OpenAlex
- W2119504728
- Cited by
- 2,292
- References
- 21
- Citations by year
- 2026: 58 · 2025: 91 · 2024: 110 · 2023: 141 · 2022: 139 · 2021: 150 · 2020: 152 · 2019: 131 · 2018: 146 · 2017: 145 · 2016: 157 · 2015: 134 · 2014: 163 · 2013: 163 · 2012: 160
- FWCI
- 116.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P50CA092629)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- castration-resistant prostate cancer, androgen receptor antagonists, enzalutamide, androgen receptor, bicalutamide, nonsteroidal antiandrogens, androgen receptor nuclear translocation, coactivator recruitment, prostate-specific antigen, oral anticancer drugs, drug development
- MeSH terms
- Androgen Antagonists, Anilides, Animals, Antineoplastic Agents, Benzamides, Biological Availability, Cell Nucleus, DNA, Drug Screening Assays, Antitumor, Humans, Male, Nitriles, Phenylthiohydantoin, Prostatic Neoplasms, Receptors, Androgen, Tosyl Compounds, Transcription, Genetic, Gene Expression Regulation, Neoplastic, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
